CEO-hunting Sanofi tried to tempt AstraZeneca’s Soriot: Bloomberg

Tracy Staton Bernstein analyst Tim Anderson figures Sanofi would do well to look outside the company for its new CEO, like AstraZeneca did with its new-ish chief, Pascal Soriot. Well, ...

Sanofi CEO Viehbacher ousted unanimously by its board

Alok Saboo FierceBiotech News

Chris Viehbacher leaving Sanofi without a U.S.-style windfall

John Carroll For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts ...

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

Tracy Staton When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing ...

Sanofi joins list of Big Pharmas fielding bribery allegations

Tracy Staton Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower ...

It’s megablockbuster halfsies for Sanofi, Amgen in next new cholesterol market

Tracy Staton When is cholesterol fighting a game of six of one, half dozen of the other? Could be when the contest is between Amgen and its PCSK9 inhibitor evolocumab, and Sanofi and ...

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

John Carroll FierceBiotech News

Sanofi, Regeneron pay $67.5M for a regulatory shortcut in blockbuster PCSK9 race with Amgen

John Carroll Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening ...

Sanofi and Regneron prep their cardio contender for FDA review after a Phase III sweep

Damian Garde Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew Phase III trials in which the drug ...

Reuters: Sanofi in $8.5B sell-off talks with Mylan, Abbott, private equity

Tracy Staton We know plenty of Big Pharma companies are hawking portfolios of old products. What we don't know is who might buy them. One answer came earlier this week, when Mylan ...

Regeneron, Sanofi herald a blockbuster contender with groundbreaking study

John Carroll If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data ...

Sanofi hits Lilly with more Lantus infringement charges

Carly Helfand Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS